Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,marketState,shortName,market,exchangeDataDelayedBy,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,HBMK,8540178,52189000,396010,,-5287,,-5269,657036,1033204,-19842,-19842,,-55446,,,,-18,2012626,2032468,979422,14555,,-5269,-5269,2075652,5823848,7826219,10615830,1566393,18442049,52189,1562359,3100363,1639430,4799937,7826219,1639430,4416164,11950233,1360694,3815436,1712300,45940.0,13663.0,5297.0,5297.0,-1068396.0,-820680.0,943.0,-840583.0,157617.0,13663.0,-148089.0,136217.0,,4124014,en-US,US,EQUITY,False,Delayed Quote,USD,-0.018,0.203,0.04221389,-0.022313891,-0.5285912,0.04428217,-0.024382168,-0.5506092,25964126,0.09802956,15,America/New_York,EDT,-14400000,4,0.0,0.0199 - 0.0199,0.0199,0.0,0.0,0,0,finmb_114828089,PRE,HUBEI MINKANG PHARMACEUTICAL LT,us_market,0,PNK,False,False,0.0199,1629299032,0.0,0.01,0.0199,0.0199,11500,Other OTC,Hubei Minkang Pharmaceutical Ltd.,USD,1824,0,0.014799999,2.9019606,0.0051 - 0.1,-0.0801,-0.801,0.0051,0.1,-317.36,,,0.1,0.0051,0.0422,0.0443,1.82k,,52.19M,,,,,,,,,,,,,,,0.00%,,,1:8,"Oct 20, 2010","Dec 30, 2013","Sep 29, 2014",-9.30%,-8.88%,-2.93%,-8.65%,10.33M,0.20,-53.40%,6.29M,-191.4k,-960.94k,-0.0180,,4.8M,0.09,3.25M,30.61,1.53,0.20,-805.1k,-546.2k,Value,408864,Healthcare,472,"Hubei Minkang Pharmaceutical Ltd. is engaged in the research, development, manufacture, and marketing of traditional Chinese medicine (TCM) and chemical pharmaceuticals. The company produces 21 products, which include 5 prescription TCM products, 1 chemical or western-style medicine, and 15 over-the-counter (OTC) products in various product types, including pills, tablets, capsules, granules, oral liquids, syrups, and mixtures and injections in approximately 400 formulations and dosages. Its principal products comprise Yinxing Damo Zhusheye, a chemical medication injectable for the prevention and treatment of coronary heart disease; An Ka Huangmin Jiaonang, a chemical medication that relieves cold and flu symptoms, including fever, headache, sore throat, and sneezing; Xumeian Capsule, a prescription TCM medication used for leucopenia; Wei C Yinqiao Pian, an OTC pill used for relieving cold and flu symptoms, such as body aches, cough, fever, headache, and sore throat; and Shuxin Koufouye, a prescription TCM oral medication for promoting blood circulation and relieving chest pain, shortness of breath, and fatigue associated with coronary heart disease. The company sells its products through distributors in the People's Republic of China, the United States, Japan, Vietnam, Malaysia, Singapore, the Philippines, Hong Kong, Indonesia, and various European countries. Hubei Minkang Pharmaceutical Ltd. was founded in 2003 and is based in Singapore.",Singapore,65 6747 7883,1388448000,Singapore,http://www.minkang.com.cn,86400,Mintwell Building,Drug Manufacturers—Specialty & Generic,"55 Ubi Avenue, No. 03-01"
t-1,HBMK,8481867,52189000,21219,,-631814,,-645072,1103508,534826,-589901,-589901,,-54937,,,,13258,1681211,2271112,1146385,-41913,,-645072,-645072,2136517,5823848,9252769,10618384,2897702,19871153,52189,947283,3105632,1636715,5620617,9252769,1636715,4510878,13223758,1942725,4220270,1652067,-340759.0,13666.0,-43004.0,-43004.0,1156093.0,312717.0,7362.0,334693.0,158591.0,13666.0,76167.0,-89395.0,,3970989,en-US,US,EQUITY,False,Delayed Quote,USD,-0.018,0.203,0.04221389,-0.022313891,-0.5285912,0.04428217,-0.024382168,-0.5506092,25964126,0.09802956,15,America/New_York,EDT,-14400000,4,0.0,0.0199 - 0.0199,0.0199,0.0,0.0,0,0,finmb_114828089,PRE,HUBEI MINKANG PHARMACEUTICAL LT,us_market,0,PNK,False,False,0.0199,1629299032,0.0,0.01,0.0199,0.0199,11500,Other OTC,Hubei Minkang Pharmaceutical Ltd.,USD,1824,0,0.014799999,2.9019606,0.0051 - 0.1,-0.0801,-0.801,0.0051,0.1,-317.36,,,0.1,0.0051,0.0422,0.0443,1.82k,,52.19M,,,,,,,,,,,,,,,0.00%,,,1:8,"Oct 20, 2010","Dec 30, 2013","Sep 29, 2014",-9.30%,-8.88%,-2.93%,-8.65%,10.33M,0.20,-53.40%,6.29M,-191.4k,-960.94k,-0.0180,,4.8M,0.09,3.25M,30.61,1.53,0.20,-805.1k,-546.2k,Value,408864,Healthcare,472,"Hubei Minkang Pharmaceutical Ltd. is engaged in the research, development, manufacture, and marketing of traditional Chinese medicine (TCM) and chemical pharmaceuticals. The company produces 21 products, which include 5 prescription TCM products, 1 chemical or western-style medicine, and 15 over-the-counter (OTC) products in various product types, including pills, tablets, capsules, granules, oral liquids, syrups, and mixtures and injections in approximately 400 formulations and dosages. Its principal products comprise Yinxing Damo Zhusheye, a chemical medication injectable for the prevention and treatment of coronary heart disease; An Ka Huangmin Jiaonang, a chemical medication that relieves cold and flu symptoms, including fever, headache, sore throat, and sneezing; Xumeian Capsule, a prescription TCM medication used for leucopenia; Wei C Yinqiao Pian, an OTC pill used for relieving cold and flu symptoms, such as body aches, cough, fever, headache, and sore throat; and Shuxin Koufouye, a prescription TCM oral medication for promoting blood circulation and relieving chest pain, shortness of breath, and fatigue associated with coronary heart disease. The company sells its products through distributors in the People's Republic of China, the United States, Japan, Vietnam, Malaysia, Singapore, the Philippines, Hong Kong, Indonesia, and various European countries. Hubei Minkang Pharmaceutical Ltd. was founded in 2003 and is based in Singapore.",Singapore,65 6747 7883,1388448000,Singapore,http://www.minkang.com.cn,86400,Mintwell Building,Drug Manufacturers—Specialty & Generic,"55 Ubi Avenue, No. 03-01"
t-2,HBMK,9053911,52189000,9211,,-78065,,-82284,1296832,1209298,-96745,-96745,,-54615,,,,4219,2885436,2982181,1676138,18680,,-82284,-82284,2195599,5823848,9252684,11249510,2502723,20502194,52189,959889,3750704,1622769,5307900,9252684,1622769,4602814,13703781,2655197,4319469,1976819,-296384.0,13637.0,-6294.0,-6294.0,-512397.0,-926293.0,-45058.0,-888578.0,159450.0,13637.0,213573.0,-194158.0,,4451097,en-US,US,EQUITY,False,Delayed Quote,USD,-0.018,0.203,0.04221389,-0.022313891,-0.5285912,0.04428217,-0.024382168,-0.5506092,25964126,0.09802956,15,America/New_York,EDT,-14400000,4,0.0,0.0199 - 0.0199,0.0199,0.0,0.0,0,0,finmb_114828089,PRE,HUBEI MINKANG PHARMACEUTICAL LT,us_market,0,PNK,False,False,0.0199,1629299032,0.0,0.01,0.0199,0.0199,11500,Other OTC,Hubei Minkang Pharmaceutical Ltd.,USD,1824,0,0.014799999,2.9019606,0.0051 - 0.1,-0.0801,-0.801,0.0051,0.1,-317.36,,,0.1,0.0051,0.0422,0.0443,1.82k,,52.19M,,,,,,,,,,,,,,,0.00%,,,1:8,"Oct 20, 2010","Dec 30, 2013","Sep 29, 2014",-9.30%,-8.88%,-2.93%,-8.65%,10.33M,0.20,-53.40%,6.29M,-191.4k,-960.94k,-0.0180,,4.8M,0.09,3.25M,30.61,1.53,0.20,-805.1k,-546.2k,Value,408864,Healthcare,472,"Hubei Minkang Pharmaceutical Ltd. is engaged in the research, development, manufacture, and marketing of traditional Chinese medicine (TCM) and chemical pharmaceuticals. The company produces 21 products, which include 5 prescription TCM products, 1 chemical or western-style medicine, and 15 over-the-counter (OTC) products in various product types, including pills, tablets, capsules, granules, oral liquids, syrups, and mixtures and injections in approximately 400 formulations and dosages. Its principal products comprise Yinxing Damo Zhusheye, a chemical medication injectable for the prevention and treatment of coronary heart disease; An Ka Huangmin Jiaonang, a chemical medication that relieves cold and flu symptoms, including fever, headache, sore throat, and sneezing; Xumeian Capsule, a prescription TCM medication used for leucopenia; Wei C Yinqiao Pian, an OTC pill used for relieving cold and flu symptoms, such as body aches, cough, fever, headache, and sore throat; and Shuxin Koufouye, a prescription TCM oral medication for promoting blood circulation and relieving chest pain, shortness of breath, and fatigue associated with coronary heart disease. The company sells its products through distributors in the People's Republic of China, the United States, Japan, Vietnam, Malaysia, Singapore, the Philippines, Hong Kong, Indonesia, and various European countries. Hubei Minkang Pharmaceutical Ltd. was founded in 2003 and is based in Singapore.",Singapore,65 6747 7883,1388448000,Singapore,http://www.minkang.com.cn,86400,Mintwell Building,Drug Manufacturers—Specialty & Generic,"55 Ubi Avenue, No. 03-01"
t-3,HBMK,9151499,52189000,33185,,-252310,,-228313,1748431,1570614,-211002,-211002,,-55160,,,,-23997,3751485,3962487,2180871,-41308,,-228313,-228313,2275836,5823848,10187785,11427335,2994790,21615120,52189,1557350,3832988,1718310,6234193,10187785,1718310,4740083,14599201,2530694,3984602,2277513,-464297.0,23885.0,-19497.0,-19497.0,426296.0,619244.0,25487.0,589369.0,250433.0,13963.0,-108642.0,632779.0,12961.0,4411416,en-US,US,EQUITY,False,Delayed Quote,USD,-0.018,0.203,0.04221389,-0.022313891,-0.5285912,0.04428217,-0.024382168,-0.5506092,25964126,0.09802956,15,America/New_York,EDT,-14400000,4,0.0,0.0199 - 0.0199,0.0199,0.0,0.0,0,0,finmb_114828089,PRE,HUBEI MINKANG PHARMACEUTICAL LT,us_market,0,PNK,False,False,0.0199,1629299032,0.0,0.01,0.0199,0.0199,11500,Other OTC,Hubei Minkang Pharmaceutical Ltd.,USD,1824,0,0.014799999,2.9019606,0.0051 - 0.1,-0.0801,-0.801,0.0051,0.1,-317.36,,,0.1,0.0051,0.0422,0.0443,1.82k,,52.19M,,,,,,,,,,,,,,,0.00%,,,1:8,"Oct 20, 2010","Dec 30, 2013","Sep 29, 2014",-9.30%,-8.88%,-2.93%,-8.65%,10.33M,0.20,-53.40%,6.29M,-191.4k,-960.94k,-0.0180,,4.8M,0.09,3.25M,30.61,1.53,0.20,-805.1k,-546.2k,Value,408864,Healthcare,472,"Hubei Minkang Pharmaceutical Ltd. is engaged in the research, development, manufacture, and marketing of traditional Chinese medicine (TCM) and chemical pharmaceuticals. The company produces 21 products, which include 5 prescription TCM products, 1 chemical or western-style medicine, and 15 over-the-counter (OTC) products in various product types, including pills, tablets, capsules, granules, oral liquids, syrups, and mixtures and injections in approximately 400 formulations and dosages. Its principal products comprise Yinxing Damo Zhusheye, a chemical medication injectable for the prevention and treatment of coronary heart disease; An Ka Huangmin Jiaonang, a chemical medication that relieves cold and flu symptoms, including fever, headache, sore throat, and sneezing; Xumeian Capsule, a prescription TCM medication used for leucopenia; Wei C Yinqiao Pian, an OTC pill used for relieving cold and flu symptoms, such as body aches, cough, fever, headache, and sore throat; and Shuxin Koufouye, a prescription TCM oral medication for promoting blood circulation and relieving chest pain, shortness of breath, and fatigue associated with coronary heart disease. The company sells its products through distributors in the People's Republic of China, the United States, Japan, Vietnam, Malaysia, Singapore, the Philippines, Hong Kong, Indonesia, and various European countries. Hubei Minkang Pharmaceutical Ltd. was founded in 2003 and is based in Singapore.",Singapore,65 6747 7883,1388448000,Singapore,http://www.minkang.com.cn,86400,Mintwell Building,Drug Manufacturers—Specialty & Generic,"55 Ubi Avenue, No. 03-01"
